Compass Therapeutics, Inc. (NasdaqCM: CMPX)
Health Care · Biotechnology · US
$2.53
+5.42% today · -20.5% 1Y
Compass Therapeutics, Inc. (NasdaqCM: CMPX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $432.21M and employs 39 people.
Over the last twelve months the share price has lost 20.5%, trading between 1.61 and 6.88.
Tweenvest scores Compass Therapeutics, Inc. across four factors: quality 30/100. Its strongest factor is quality.
CMPX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $432.21M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- $6.88
- 52-week low
- $1.61
- Avg volume (3M)
- —
- Shares outstanding
- 180.09M
- Employees
- 39
- Next earnings
- —
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
- ISIN
- US20454B1044
- Founded
- 2014
- Listed since
- Apr 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.